Key Highlights

  • Q3 2026 total Revenue of $1.56 billion and total net sales of $1.32 billion, each up 14% year over year.
  • Jakafi/Jakafi XR net sales of $827 million, up 4%; Opzelura net sales of $255 million, up 36%.
  • Hematology and Oncology net sales of $235 million, up 38% year over year.
  • Raised 2026 full-year guidance for Opzelura net sales, Hematology and Oncology net sales, and total net sales.

Revenue Growth Across Core Products

Incyte Corporation (NASDAQ:INCY) reported Q3 2026 total revenue of $1.56 billion, an increase of 14% compared to the third quarter of 2025. Total net product sales were $1.32 billion, also up 14% year over year, as growth across Opzelura and the Hematology and Oncology portfolio more than offset a more modest increase in Jakafi, the company's flagship myelofibrosis treatment.

Jakafi (ruxolitinib) and its extended-release formulation Jakafi XR generated combined net sales of $827 million in Q3 2026, a 4% increase over the prior-year period. While Jakafi's growth rate moderated compared to historical levels, management highlighted strong underlying Demand and continued patient uptake across its approved indications in myelofibrosis and polycythemia vera.

Opzelura and Hematology Portfolio Surge

Opzelura (ruxolitinib cream) delivered Q3 2026 net sales of $255 million, representing 36% growth year over year. The topical JAK inhibitor, approved for atopic dermatitis and vitiligo, is benefiting from expanded commercial adoption and label utilization as more dermatologists and their patients experience its differentiated efficacy profile. Management raised the full-year 2026 net sales guidance for Opzelura based on the continued trajectory.

Incyte's Hematology and Oncology portfolio—which includes pipeline-derived products and partner royalties beyond Jakafi—reported net sales of $235 million in Q3 2026, up 38% year over year. This segment captures the growing contribution from newer hematology agents and oncology collaborations. Management also raised full-year guidance for this segment, citing continued commercial execution.

Late-Stage Pipeline Progress

Incyte provided pipeline updates across several development programs during the quarter. Phase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativa are expected by year-end 2026, potentially providing near-term catalysts for label expansion.

In hematology, the company is advancing multiple registrational programs, including Phase 3 studies underway or planned for INCA033989 in essential thrombocythemia and myelofibrosis, as well as latarcibart in von Willebrand disease. Early-stage oncology data for INCB161734 and INCA033890 support an expanding GI Oncology development strategy, with multiple ongoing and planned registrational studies in 2027.

Raised 2026 Full-Year Guidance

Incyte raised its full-year 2026 financial guidance for Opzelura net sales, Hematology and Oncology net sales, and total net sales, reflecting the stronger-than-expected performance through the first three quarters of the year. The guidance increase signals management's confidence that the growth rates observed in Q3 are sustainable through the remainder of 2026.

The company's commercial infrastructure, spanning sales forces across dermatology, hematology, and oncology, and its disciplined pipeline Investment across early, mid, and late-stage programs, positions Incyte for diversified growth as the Jakafi Franchise matures and next-generation Assets progress toward commercialization.

Incyte delivered a broad-based revenue beat in Q3 2026, with Opzelura and Hematology growing 36% and 38% respectively to complement steady Jakafi performance. The raised full-year guidance and multiple approaching catalysts across its late-stage pipeline—including year-end readouts in prurigo nodularis and hidradenitis suppurativa—reinforce the company's growth profile heading into 2027.

What was Incyte's total revenue in Q3 2026?

Incyte reported total revenue of $1.56 billion and total net product sales of $1.32 billion in Q3 2026, each up 14% year over year.

How did Opzelura perform in Q3 2026?

Opzelura (ruxolitinib cream) net sales were $255 million in Q3 2026, up 36% year over year, driven by expanding commercial adoption in atopic dermatitis and vitiligo.

What pipeline catalysts does Incyte expect by year-end 2026?

Incyte expects Phase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativa by year-end 2026.

Did Incyte raise its full-year 2026 guidance?

Yes, Incyte raised its 2026 full-year guidance for Opzelura net sales, Hematology and Oncology net sales, and total net sales following Q3 outperformance.